{"article":{"annotation":{"article_id":"united-therapeutics-first-uthymokidney-transplant-extend-trial-2026","available_at":"2026-11-20T15:14:54.104179Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"c3926b36d02eb87784880e23d42dc8ad21d91fc171cbbb16b83406e53d9abb03","input_sha256":"eca8a40e820e47c07a71e358d787187b38f3abf0c0c86d06787a64aaf8205235","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"US","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthymokidney-extend-study-press-release-20-nov-2026.pdf"]}],"geometry":null,"id":"iso3166-1:US","kind":"country-or-area","labels":{"ar":"الولايات المتحدة الأمريكية","en":"United States of America","es":"Estados Unidos de América","fr":"États-Unis d’Amérique"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Health, disease","source_urls":["https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthymokidney-extend-study-press-release-20-nov-2026.pdf"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["United Therapeutics Corporation announced on 20 November 2026 that the first clinical xenotransplant has been completed in its EXTEND study evaluating the investigational UThymoKidney in patients with end-stage renal disease. The surgical procedure took place at NYU Langone Health, led by Robert Montgomery, chair of the Department of Surgery at NYU Grossman School of Medicine and director of the NYU Langone Transplant Institute. The company described EXTEND as the first clinical trial designed to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage kidney failure, and the second clinical trial in its manufactured xeno-organ pipeline.","The EXTEND study, registered as NCT07224763, is structured as a multicenter, open-label, combination Phase 1/2/3 clinical trial intended to support a future Biologics License Application with the U.S. Food and Drug Administration. Rather than separating safety, dose-finding and pivotal efficacy into distinct sequential trials, this phaseless design progresses through staged clinical gates. Eligible participants are patients with end-stage renal disease who are not eligible for conventional human kidney transplantation, or who are listed on an Organ Procurement and Transplantation Network waitlist but are statistically more likely to die or remain untransplanted within five years than to receive a human donor organ.","Unlike multi-gene-edited porcine organs tested in other clinical studies, the UThymoKidney is derived from a pig with a single genetic modification and incorporates porcine thymic tissue grafted beneath the kidney capsule. The single edit inactivates the porcine gene responsible for synthesising alpha-gal, a cell-surface sugar that triggers immediate hyperacute rejection when porcine tissue enters the human bloodstream. The co-transplanted porcine thymus tissue is intended to condition the recipient's immune system over time to recognise the organ as self, aiming to lower the likelihood of long-term rejection alongside required immunosuppressive therapy.","Under the protocol outlined by United Therapeutics, each participant who receives a UThymoKidney undergoes a 24-week post-transplant follow-up period during which all primary efficacy endpoints and safety assessments are evaluated. Following the 24-week window, recipients will remain under lifelong monitoring for graft function and potential zoonotic infections. Key efficacy measures at 24 weeks include participant survival rate, UThymoKidney survival rate, change in measured glomerular filtration rate, donor-specific hyporesponsiveness assessed by the Mixed Lymphocyte Reaction assay, and quality of life measured across four standardised instruments, alongside overall patient and graft survival times.","Safety oversight in the trial tracks the incidence of adverse events and serious adverse events, all-cause mortality, proteinuria, zoonotic infections and opportunistic infections associated with immunosuppression. The first six transplants are planned across two clinical centers, with a mandatory 12-week waiting interval between the first and second procedures. Once all six initial recipients have reached at least 12 weeks post-transplant, an Independent Data Monitoring Committee will review accumulated safety and efficacy data to determine whether the study should proceed. United Therapeutics plans to present those six-patient results to the FDA before adding centers or expanding enrolment.","EXTEND runs alongside two other xeno-organ programs at United Therapeutics. The EXPAND trial, registered as NCT06878560, is a multicenter open-label registration study evaluating the company's UKidney in patients with end-stage renal disease at NYU Langone Health and Northwestern Medicine. A third study, EXPRESS, is planned as an open-label trial of the investigational UHeart in advanced heart failure, beginning at a single site. Both UKidney and UHeart are derived from pigs carrying 10 genetic edits, comprising six added human genes to promote immunological compatibility and four knocked-out porcine genes to reduce rejection risk and moderate organ growth.","Company leadership and the surgical team framed the milestone as a disciplined step rather than proof of clinical efficacy. Jayme Locke, chief medical officer for xenotransplantation at United Therapeutics, noted that the launch reflects years of scientific, facility and regulatory work, while Leigh Peterson, executive vice president for product development and xenotransplantation, emphasised methodical progression with patient safety first. Montgomery pointed to the daily mortality among patients awaiting human kidneys and said the EXTEND protocol offers a rigorous test of whether thymokidney xenotransplantation can deliver measurable benefit for people with few remaining clinical options.","United Therapeutics cited national kidney disease figures to underscore the scale of the supply gap. According to data from the American Kidney Fund and the 2024 United States Renal Data System Annual Report referenced in the release, approximately 830,000 people in the United States live with kidney failure, more than 550,000 depend on dialysis and over 90,000 are on the kidney transplant waiting list, while only about 22,000 deceased-donor kidney transplants occurred in 2025. Three years after starting dialysis, only 12 percent of patients had been placed on the national waitlist and more than 40 percent had died without receiving a transplant.","The company stressed that UThymoKidney, UKidney and UHeart are all investigational products not approved in any jurisdiction for any indication. Completing the first transplant establishes procedural feasibility in the EXTEND study, but clinical durability, immunological tolerance, infection surveillance and regulatory acceptability will only become clear as the 12-week interval, the six-patient monitoring review and the 24-week endpoint evaluations unfold. Future clinical disclosures and FDA feedback will determine whether the single-edit thymokidney platform can scale into a larger pivotal cohort."],"sections":[]},"corrections":[],"country":"US","data":{"blocks":[{"description":{"ar":"أرقام مختارة لتصميم التجربة السريرية والفشل الكلوي في الولايات المتحدة وردت في بيان يونايتد ثيرابيوتكس.","de":"Ausgewählte Angaben zum Studiendesign und zu Nierenversagen in den USA aus der Pressemitteilung von United Therapeutics.","en":"Selected clinical trial design and US kidney failure figures reported in the United Therapeutics press release.","es":"Cifras seleccionadas sobre el diseño del ensayo clínico y la insuficiencia renal en Estados Unidos tomadas del comunicado de United Therapeutics.","fr":"Chiffres sélectionnés relatifs au protocole clinique et à l'insuffisance rénale aux États-Unis tirés du communiqué de United Therapeutics.","pt":"Valores selecionados sobre o desenho do ensaio clínico e a insuficiência renal nos Estados Unidos divulgados no comunicado da United Therapeutics.","tr":"United Therapeutics basın bülteninde bildirilen seçilmiş klinik çalışma tasarımı ve ABD böbrek yetmezliği rakamları."},"id":"reported-figures","items":[{"basis":"target","label":{"ar":"المجموعة الأولى في دراسة EXTEND قبل مراجعة إدارة الغذاء والدواء","de":"Erste EXTEND-Patientengruppe vor FDA-Prüfung","en":"Initial EXTEND study cohort before FDA review","es":"Cohorte inicial del estudio EXTEND antes de la revisión de la FDA","fr":"Cohorte initiale de l'essai EXTEND avant examen par la FDA","pt":"Coorte inicial do estudo EXTEND antes da revisão pela FDA","tr":"FDA incelemesi öncesi ilk EXTEND hasta grubu"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"united-states","id":"g20261120-d7-unither-1","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":6},{"basis":"observed","label":{"ar":"فترة المتابعة الأساسية بعد الزراعة في دراسة EXTEND","de":"Primäre Nachbeobachtungsdauer nach Transplantation in EXTEND","en":"Post-transplant primary follow-up window in EXTEND","es":"Periodo principal de seguimiento tras el trasplante en EXTEND","fr":"Durée du suivi principal post-greffe dans EXTEND","pt":"Período principal de acompanhamento pós-transplante no EXTEND","tr":"EXTEND çalışmasında nakil sonrası temel takip süresi"},"measure":{"aggregation":"unspecified","frequency":"irregular","geography":"united-states","id":"g20261120-d7-unither-2","periodRole":"announcement-date","unitCode":"week"},"period":"2026-11-20","unit":"weeks","value":24},{"basis":"estimate","label":{"ar":"العدد التقريبي لمرضى الفشل الكلوي في الولايات المتحدة","de":"Ungefähre Zahl der Patienten mit Nierenversagen in den USA","en":"Approximate US patients with kidney failure","es":"Número aproximado de pacientes con insuficiencia renal en Estados Unidos","fr":"Nombre approximatif de patients atteints d'insuffisance rénale aux États-Unis","pt":"Número aproximado de doentes com insuficiência renal nos Estados Unidos","tr":"ABD'de yaklaşık böbrek yetmezliği hastası sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"united-states","id":"g20261120-d7-unither-3","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":830000,"valueQualifier":"approximate"},{"basis":"estimate","label":{"ar":"العدد التقريبي لعمليات زراعة الكلى من متبرعين متوفين في الولايات المتحدة عام 2025","de":"Ungefähre Zahl der Nierentransplantationen verstorbener Spender in den USA 2025","en":"Approximate US deceased-donor kidney transplants in 2025","es":"Número aproximado de trasplantes renales de donante fallecido en Estados Unidos en 2025","fr":"Nombre approximatif de greffes rénales de donneurs décédés aux États-Unis en 2025","pt":"Número aproximado de transplantes renais de dador falecido nos Estados Unidos em 2025","tr":"2025 yılında ABD'de yaklaşık kadavra donörlü böbrek nakli"},"measure":{"aggregation":"flow","frequency":"annual","geography":"united-states","id":"g20261120-d7-unither-4","periodRole":"reference-period","unitCode":"count"},"period":"2025","unit":"cases","value":22000,"valueQualifier":"approximate"},{"basis":"observed","label":{"ar":"نسبة مرضى غسيل الكلى المدرجين على قائمة الانتظار بعد ثلاث سنوات في الولايات المتحدة","de":"Anteil der US-Dialysepatienten auf der Warteliste nach drei Jahren","en":"Share of US dialysis patients waitlisted after three years","es":"Porcentaje de pacientes en diálisis en lista de espera tras tres años en Estados Unidos","fr":"Part des patients dialysés inscrits sur liste d'attente après trois ans aux États-Unis","pt":"Percentagem de doentes em diálise em lista de espera após três anos nos Estados Unidos","tr":"Üç yıl sonunda bekleme listesine alınan ABD diyaliz hastaları oranı"},"measure":{"aggregation":"rate","frequency":"annual","geography":"united-states","id":"g20261120-d7-unither-5","periodRole":"reference-period","unitCode":"percent"},"period":"2024","unit":"percent","value":12}],"methodology":{"ar":"تحتفظ الأرقام بالفترة والسكان والنطاق والتعريفات التي يحددها المصدر، وتُصنف التقديرات والأهداف بحسب أساسها دون استنتاج أي قيمة مفقودة.","de":"Die Zahlen behalten Zeitraum, Bezugsgruppe, Umfang und Definitionen der Quelle bei. Schätzungen und Ziele sind nach ihrer Grundlage gekennzeichnet.","en":"Figures retain the source's stated period, population, scope and definitions. Estimates and targets are labeled by basis. No missing value is inferred.","es":"Las cifras conservan el periodo, la población, el alcance y las definiciones indicados por la fuente. Las estimaciones y objetivos se identifican según su base.","fr":"Les chiffres conservent la période, la population, le périmètre et les définitions indiqués par la source. Les estimations et objectifs sont qualifiés selon leur base.","pt":"Os valores mantêm o período, a população, o âmbito e as definições indicados pela fonte. Estimativas e metas são identificadas segundo a respetiva base.","tr":"Rakamlar kaynağın belirttiği dönem, nüfus, kapsam ve tanımları korur. Tahminler ve hedefler dayanaklarına göre etiketlenir. Eksik değerler çıkarımla tamamlanmaz."},"sourceUrls":["https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthymokidney-extend-study-press-release-20-nov-2026.pdf"],"title":{"ar":"الأرقام الرئيسية المعلنة","de":"Wichtige gemeldete Kennzahlen","en":"Key reported figures","es":"Cifras clave comunicadas","fr":"Principaux chiffres déclarés","pt":"Principais valores reportados","tr":"Bildirilen temel rakamlar"},"type":"metrics","updatedAt":"2026-11-20T14:30:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026/data/reported-figures?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026/data/reported-figures?lang=en&format=json"},"id":"reported-figures"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-a60b56b5-7ef6-537d-b60e-5d40aea5441b","event_period":"2026-11-20","event_period_basis":"event-or-reference-period","id":"united-therapeutics-first-uthymokidney-transplant-extend-trial-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-20T15:14:29+00:00","publication_basis":"publication-record","published_at":"2026-11-20T15:14:29+00:00","reading_minutes":5,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"united-therapeutics-first-uthymokidney-transplant-extend-trial-2026","sources":[{"checkedAt":"2026-11-20","name":"United Therapeutics Corporation, First Transplant in EXTEND Clinical Trial of UThymoKidney","publishedAt":"2026-11-20","url":"https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthymokidney-extend-study-press-release-20-nov-2026.pdf"}],"summary":"United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.","text":"United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.\n\nUnited Therapeutics Corporation announced on 20 November 2026 that the first clinical xenotransplant has been completed in its EXTEND study evaluating the investigational UThymoKidney in patients with end-stage renal disease. The surgical procedure took place at NYU Langone Health, led by Robert Montgomery, chair of the Department of Surgery at NYU Grossman School of Medicine and director of the NYU Langone Transplant Institute. The company described EXTEND as the first clinical trial designed to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage kidney failure, and the second clinical trial in its manufactured xeno-organ pipeline.\n\nThe EXTEND study, registered as NCT07224763, is structured as a multicenter, open-label, combination Phase 1/2/3 clinical trial intended to support a future Biologics License Application with the U.S. Food and Drug Administration. Rather than separating safety, dose-finding and pivotal efficacy into distinct sequential trials, this phaseless design progresses through staged clinical gates. Eligible participants are patients with end-stage renal disease who are not eligible for conventional human kidney transplantation, or who are listed on an Organ Procurement and Transplantation Network waitlist but are statistically more likely to die or remain untransplanted within five years than to receive a human donor organ.\n\nUnlike multi-gene-edited porcine organs tested in other clinical studies, the UThymoKidney is derived from a pig with a single genetic modification and incorporates porcine thymic tissue grafted beneath the kidney capsule. The single edit inactivates the porcine gene responsible for synthesising alpha-gal, a cell-surface sugar that triggers immediate hyperacute rejection when porcine tissue enters the human bloodstream. The co-transplanted porcine thymus tissue is intended to condition the recipient's immune system over time to recognise the organ as self, aiming to lower the likelihood of long-term rejection alongside required immunosuppressive therapy.\n\nUnder the protocol outlined by United Therapeutics, each participant who receives a UThymoKidney undergoes a 24-week post-transplant follow-up period during which all primary efficacy endpoints and safety assessments are evaluated. Following the 24-week window, recipients will remain under lifelong monitoring for graft function and potential zoonotic infections. Key efficacy measures at 24 weeks include participant survival rate, UThymoKidney survival rate, change in measured glomerular filtration rate, donor-specific hyporesponsiveness assessed by the Mixed Lymphocyte Reaction assay, and quality of life measured across four standardised instruments, alongside overall patient and graft survival times.\n\nSafety oversight in the trial tracks the incidence of adverse events and serious adverse events, all-cause mortality, proteinuria, zoonotic infections and opportunistic infections associated with immunosuppression. The first six transplants are planned across two clinical centers, with a mandatory 12-week waiting interval between the first and second procedures. Once all six initial recipients have reached at least 12 weeks post-transplant, an Independent Data Monitoring Committee will review accumulated safety and efficacy data to determine whether the study should proceed. United Therapeutics plans to present those six-patient results to the FDA before adding centers or expanding enrolment.\n\nEXTEND runs alongside two other xeno-organ programs at United Therapeutics. The EXPAND trial, registered as NCT06878560, is a multicenter open-label registration study evaluating the company's UKidney in patients with end-stage renal disease at NYU Langone Health and Northwestern Medicine. A third study, EXPRESS, is planned as an open-label trial of the investigational UHeart in advanced heart failure, beginning at a single site. Both UKidney and UHeart are derived from pigs carrying 10 genetic edits, comprising six added human genes to promote immunological compatibility and four knocked-out porcine genes to reduce rejection risk and moderate organ growth.\n\nCompany leadership and the surgical team framed the milestone as a disciplined step rather than proof of clinical efficacy. Jayme Locke, chief medical officer for xenotransplantation at United Therapeutics, noted that the launch reflects years of scientific, facility and regulatory work, while Leigh Peterson, executive vice president for product development and xenotransplantation, emphasised methodical progression with patient safety first. Montgomery pointed to the daily mortality among patients awaiting human kidneys and said the EXTEND protocol offers a rigorous test of whether thymokidney xenotransplantation can deliver measurable benefit for people with few remaining clinical options.\n\nUnited Therapeutics cited national kidney disease figures to underscore the scale of the supply gap. According to data from the American Kidney Fund and the 2024 United States Renal Data System Annual Report referenced in the release, approximately 830,000 people in the United States live with kidney failure, more than 550,000 depend on dialysis and over 90,000 are on the kidney transplant waiting list, while only about 22,000 deceased-donor kidney transplants occurred in 2025. Three years after starting dialysis, only 12 percent of patients had been placed on the national waitlist and more than 40 percent had died without receiving a transplant.\n\nThe company stressed that UThymoKidney, UKidney and UHeart are all investigational products not approved in any jurisdiction for any indication. Completing the first transplant establishes procedural feasibility in the EXTEND study, but clinical durability, immunological tolerance, infection surveillance and regulatory acceptability will only become clear as the 12-week interval, the six-patient monitoring review and the 24-week endpoint evaluations unfold. Future clinical disclosures and FDA feedback will determine whether the single-edit thymokidney platform can scale into a larger pivotal cohort.","title":"United Therapeutics completes first UThymoKidney xenotransplant in EXTEND trial","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},{"api_url":"https://newsverum.com/api/v1/articles/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"}],"url":"https://newsverum.com/en/news/united-therapeutics-first-uthymokidney-transplant-extend-trial-2026"},"version":"1"}
